Consensus H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Delayed Nasdaq Copenhagen Other stock markets 10:59:58 2024-05-08 am EDT			5-day change	1st Jan Change
34.58 ^DKK	+1.11%		+1.59%	+5.56%

Apr. 09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
Apr. 09	Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	CI

Evolution of the average Target Price on H. Lundbeck A/S

Price target over the last 5 years

History of analyst recommendation changes

66b08e708de1da98aa444.tEeU1KFKNbckrdJlBcyvXauYdxlhQVb_pnVpI7uU3ik.2iHQl-hyVu984oYkR_3EKs2sM10nJSCr7hwede_9vHbyMuSY_gBn5mfVtQ~754aa0e735840e799d761df08f5eff81